Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.
Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...
GlobalData on MSN
Health Canada approves Biocon’s two denosumab biosimilars
Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.
The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...
Biocon shares jump 8% post Q4 results. Is the Street happy? Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings ...
Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.
At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...
BENGALURU, India, March 27, 2026--(BUSINESS WIRE)--Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results